Adult Leukemia

SAN DIEGO — In this video, Marlise R. Luskin, MD, MSCE, highlights updates from two groups evaluating blinatumomab and ponatinib for the treatment of acute lymphoblastic leukemia.

The FDA has approved obecabtagene autoleucel for the treatment of adults with relapsed refractory B-cell precursor acute lymphoblastic leukemia.

Three women oncologist researchers at Dana Farber Cancer Institute have been named recipients of the Damon Runyon Cancer Research Foundation Clinical Investigator Award.